Home › Funds › 2Xideas AG › EW
2Xideas AG position in EW
EDWARDS LIFESCIENCES CORP · Health Care
2Xideas AG reported holding 320,124 shares of EW (EDWARDS LIFESCIENCES CORP) in its Q3 2026 13F filing — a position valued at US$27.6M, representing 14.76% of its reported portfolio and ranking #2 among its reported holdings. 2Xideas AG has disclosed EW holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How 2Xideas AG's EW position evolved
2Xideas AG first disclosed a stake in EW in Q3 2023 at 137,391 shares (US$9.5M). The position peaked in Q2 2025 at 520,711 shares, worth US$40.7M. Across 13 filings, 2Xideas AG increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 320,124 shares valued at US$27.6M — a reduction of -20,682 shares quarter over quarter.. Notable position changes include a 26% increase in Q1 2024 (shares fell 3% over the following quarter), a 173% increase in Q2 2025 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 137.39K | $9.52M | New |
| Q4 2023 | 156.04K | $11.90M | Add |
| Q1 2024 | 196.51K | $18.78M | Add |
| Q2 2024 | 202.68K | $18.72M | Add |
| Q3 2024 | 224.08K | $14.79M | Add |
| Q4 2024 | 177.30K | $13.13M | Reduce |
| Q1 2025 | 190.58K | $13.81M | Add |
| Q2 2025 | 520.71K | $40.72M | Add |
| Q3 2025 | 486.26K | $37.82M | Reduce |
| Q4 2025 | 429.12K | $36.58M | Reduce |
| Q1 2026 | 352.08K | $28.19M | Reduce |
| Q2 2026 | 340.81K | $30.83M | Reduce |
| Q3 2026 | 320.12K | $27.63M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EW and 13F data
EW (EDWARDS LIFESCIENCES CORP) is a Health Care company. 31 other funds we track also report a position in EW — the largest reported positions include Belvedere Trading LLC (US$25.63B), DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt (US$1.18B), Ninety One UK Ltd (US$1.03B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EW
- Belvedere Trading LLC 3.30M sh · $25.63B · Q3 2026
- DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt 13.00M sh · $1.18B · Q2 2026
- Ninety One UK Ltd 11.94M sh · $1.03B · Q3 2026
- Aristotle Capital Management, LLC 8.67M sh · $783.91M · Q2 2026
- BROWN ADVISORY INC 7.37M sh · $666.33M · Q2 2026
- Artisan Partners Limited Partnership 6.09M sh · $525.69M · Q3 2026
FAQ
How long has 2Xideas AG held EW?
2Xideas AG has disclosed EW holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is 2Xideas AG's current position in EW?
As of Q3 2026, 2Xideas AG holds 320.12K shares of EW (EDWARDS LIFESCIENCES CORP), valued at $27.63M, representing 14.76% of its reported portfolio and ranking #2.
Has 2Xideas AG been buying or selling EW?
In the latest 13F filing (Q3 2026), 2Xideas AG reduced its position in EW. The position peaked in Q2 2025 at 520.71K shares.
Which other funds hold EW?
Other major institutional holders of EW include Belvedere Trading LLC, DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt, Ninety One UK Ltd, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.